Connect with us at DCAT Week! March 17-20, New York
Contact Us

BLOG

Chewable Tablets: A Guide to Formulation and Development

Chewable Tablets: A Guide to Formulation and Development

Vici Health Sciences
Formulating Fixed-Dose Combination (FDC) Drugs: Innovation through bilayer tablet technology

Formulating Fixed-Dose Combination (FDC) Drugs: Innovation through bilayer tablet technology

By: Arushi Agarwal
What is Freeze thaw (Thermal cycling) study?

What is Freeze thaw (Thermal cycling)…

By: Ramiz Mansuri, M.Pharm
What is In-Use Stability?

What is In-Use Stability?

Vici Health Sciences
Search
Does your dosage form need to be sterile? Key differences between sterile and non-sterile dosage forms

Does your dosage form need to…

By: Anish Dhanarajan, PhD
Overcoming Key Challenges in Developing Fixed-Dose Combination Tablets

Overcoming Key Challenges in Developing Fixed-Dose…

By: Anish Dhanarajan, PhD
Why CMC Experts Are Crucial for Successful Drug Development

Why CMC Experts Are Crucial for…

By: Anish Dhanarajan, PhD
Stability Testing for Pharmaceutical Drug Products

Stability Testing for Pharmaceutical Drug Products

By: Anish Dhanarajan, PhD
What is an IND?

What is an IND?

By: Anish Dhanarajan, PhD
CDMO vs CMO vs CRO: Key Differences

CDMO vs CMO vs CRO: Key…

Vici Health Sciences
Gels, Creams, Lotions, and Ointments: Key Benefits and Differences

Gels, Creams, Lotions, and Ointments: Key…

Vici Health Sciences
505(b)(1) vs 505(b)(2): Understanding the Key Differences in FDA Drug Approval Processes

505(b)(1) vs 505(b)(2): Understanding the Key…

Vici Health Sciences
Patient Compliance Through Drug Delivery Systems

Patient Compliance Through Drug Delivery Systems

By: Anish Dhanarajan, PhD
What is CMC?

What is CMC?

By: Anish Dhanarajan, PhD
Frequently Asked Question: Dissolution testing

Frequently Asked Question: Dissolution testing

By: Anish Dhanarajan, PhD
Controlled Release Explained

Controlled Release Explained

Suneel Rastogi, PhD
Obstacles in Drug Development and How to Overcome Them

Obstacles in Drug Development and How…

Vici Health Sciences
Tablet Defects and How to Overcome Them in Manufacturing

Tablet Defects and How to Overcome…

Vici Health Sciences
Understanding Bioequivalence in Generic Drug Approval

Understanding Bioequivalence in Generic Drug Approval

Vici Health Sciences
Integrating cGMP in Clinical Manufacturing

Integrating cGMP in Clinical Manufacturing

Vici Health Sciences
Essential ANDA Checklist: Key Steps to Streamline Your Filing Process

Essential ANDA Checklist: Key Steps to…

Vici Health Sciences
What is Oral Solid Dosage (OSD): A Comprehensive Guide to OSD Formulations

What is Oral Solid Dosage (OSD):…

Suneel Rastogi, PhD
Why Your Early-Stage Drug Development Needs an R&D-Focused CDMO Partner

Why Your Early-Stage Drug Development Needs…

By: Anish Dhanarajan, PhD
From R&D to Quality Control (QC): Developing QC-Friendly Analytical Methods

From R&D to Quality Control (QC):…

By: Bhavya Teja Kolla & Pingmei Wang, PhD
Phase-Appropriate Validation: How Tailored Approaches Support Cost-Effective Drug Development

Phase-Appropriate Validation: How Tailored Approaches Support…

Pingmei Wang, PhD
Non-Clinical (animal) IND Enabling Studies: What You Need to Know

Non-Clinical (animal) IND Enabling Studies: What…

By: Francesca Minale, M.Eng.
Key Pharmacokinetic Factors in Semi Solid Topical Medication Development

Key Pharmacokinetic Factors in Semi Solid…

By: Bhavya Teja Kolla
Clinical Manufacturing Explained: How CDMOs Support the Development of FDA-Approved Trial Materials

Clinical Manufacturing Explained: How CDMOs Support…

Vici Health Sciences
NDA vs. ANDA: A Comprehensive Guide to Key Differences, Processes, and Regulatory Requirements

NDA vs. ANDA: A Comprehensive Guide…

Vici Health Sciences
Stability Chambers: Testing Methods, Essential Equipment, and Applications

Stability Chambers: Testing Methods, Essential Equipment,…

Vici Health Sciences
Top 7 Questions for Small Pharma and Pharmaceutical Startups to Ask When Choosing the Right CDMO Partner

Top 7 Questions for Small Pharma…

By: Anish Dhanarajan, PhD
Semi-Solid and Semi-Liquid Dosage Forms

Semi-Solid and Semi-Liquid Dosage Forms

Vici Health Sciences
The Critical Role of Formulation Development in Product Success

The Critical Role of Formulation Development…

By: Anish Dhanarajan, PhD
The FDA’s 505(b)(2) Explained

The FDA’s 505(b)(2) Explained

By: Francesca Minale, M.Eng.
What is a CDMO and Why Does Your Company Need One?

What is a CDMO and Why…

By: Anish Dhanarajan, PhD
Permeability Enhancers for Bioavailability Improvement

Permeability Enhancers for Bioavailability Improvement

Vici Health Sciences
Muco-Adhesion Testing

Muco-Adhesion Testing

Vici Health Sciences
IVRT and IVPT: Pivotal Tools in Topical Product Development

IVRT and IVPT: Pivotal Tools in…

Vici Health Sciences
Topical Dosage Forms: Product Development Overview

Topical Dosage Forms: Product Development Overview

Vici Health Sciences
Heterocyclic Compounds, the Backbone of Small Molecule Therapeutics

Heterocyclic Compounds, the Backbone of Small…

Vici Health Sciences
Pharmaceutical Suspensions – Part 2: Formulation Development

Pharmaceutical Suspensions – Part 2: Formulation…

Vici Health Sciences
Pharmaceutical Suspension Formulations – Part 1: An Overview of Key Advantages and Desirable Properties

Pharmaceutical Suspension Formulations – Part 1:…

Vici Health Sciences
Buccal Delivery Systems (Part 3) – Improving Bioavailability through Buccal Route

Buccal Delivery Systems (Part 3) –…

Vici Health Sciences
Buccal Delivery Systems | Part 2: Applications and Dosage Forms

Buccal Delivery Systems | Part 2:…

Vici Health Sciences
Buccal Delivery Systems | Part 1: Opportunities and Challenges

Buccal Delivery Systems | Part 1:…

Vici Health Sciences
The science of pharmaceutical taste masking

The science of pharmaceutical taste masking

Vici Health Sciences
Will the US FDA accept foreign clinical trials?

Will the US FDA accept foreign…

Vici Health Sciences
FDA approval pathways: the 505b2

FDA approval pathways: the 505b2

Vici Health Sciences
Vici can now export and import DEA schedule 1-5 controlled substances to support clinical development

Vici can now export and import…

Vici Health Sciences
Nitrosamine risk evaluation and testing, what’s next?

Nitrosamine risk evaluation and testing, what’s…

Vici Health Sciences
Creating Formulation Intellectual Property during Drug Development – FAQ

Creating Formulation Intellectual Property during Drug…

Vici Health Sciences
CMO versus CDMO: what’s the difference and how this decision is make or break for early phase drug development programs

CMO versus CDMO: what’s the difference…

Vici Health Sciences
Focusing on medicine for patients with swallowing difficulties

Focusing on medicine for patients with…

Vici Health Sciences
Vici now offers cGMP API and intermediates synthesis services to support phase 1 clinical and GLP nonclinical studies

Vici now offers cGMP API and…

Vici Health Sciences
High quality formulation development upfront saves drug developers valuable time and money

High quality formulation development upfront saves…

Vici Health Sciences
The Importance of Formulation Development in Successful Drug Development

The Importance of Formulation Development in…

Vici Health Sciences

Follow Us